GENE ONLINE|News &
Opinion
Blog

2025-02-07| Trials & Approvals

Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026

by Bernice Lottering
Share To
Novo Nordisk (NOVO-B.CO) is gearing up for a new Phase III trial of CagriSema, its next-gen obesity drug and potential Wegovy (semaglutide) successor. The company …

Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026 Read More »

GO Prime with only $1.49 now

SUBSCRIBE NOW
LATEST
NUS Researchers Use Evolutionary Biology Models to Map Singapore Shophouse Architectural Development
2026-08-11
North Star Review Board Launches Nonprofit Model for Institutional Oversight
2026-08-11
City St George’s Launches €6 Million REMADE Project to Advance Circular Renovation in Urban Neighborhoods
2026-08-10
106 Adults Receive Free Dementia Screenings at Atlanta Community Organizations
2026-08-10
Digital Science Releases Two Model Context Protocol Servers for Dimensions Research Platform
2026-08-10
Boston College Chemist Receives $600,000 NSF Grant to Study Transition Metal Oxychlorides for Battery Storage
2026-08-10
Researchers Identify Related Viruses to Mitigate Koi Herpesvirus in Carp Populations
2026-08-10
READ MORE
EVENT
2026-09-02
BIO Asia Pacific (APAC Biotech & Smart Health)
Bangkok, Thailand
2026-09-16
BIOHK (16–19, Hong Kong) (Hong Kong biotech & investment)
Hong Kong
2026-10-07
BioJapan / HealthTECH JAPAN (Biotech, Medtech, Regenerative)
Yokohama, Japan
2026-10-07
Hospital Expo Tokyo (Devices & Hospital IT)
Tokyo, Japan
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
2026-10-23
ESMO Congress 2026 (Oncology Breakthroughs)
Madrid, Spain
SEE MORE
Scroll to Top